TECH OFFERS

The skincare industry is seeing an upward exponential shift in consumer preferences for natural and sustainable products with stricter regulations on materials and components bans which has been shown to result in long-term harm to the well-being of users. The current skincare chemicals and materials in the market possess various health challenges such as skin irritation and allergy where skincare and cosmetic companies are increasingly sourcing for sustainable, renewable, and safe bio-based materials. This technology presents a scalable solution to produce a bioingredient, nanofibrillated cellulose to replace petroleum-based materials in skincare.  Cellulose is an abundant material in nature, this technology develops a process to extract nanofibrillated cellulose for various applications. Nanofibrillated cellulose is a renewable biopolymer with high flexibility in structure which enables it to exhibit increased mechanical strength, optical, thermal and fluidic properties compared to cellulose. The nanostructure and rich hydroxyl groups allows for modifications in hybridization to fabricate materials ranging from films, membranes, soft gels and creams at reduced size and porosity.  The product has been validated to have excellent water retention, is highly biocompatible and can be applied as a thickening agent, emulsifiers, humectants, texture, and viscosity modifiers. Functional and cytotoxicity tests are completed to ensure the safety of the material. The technology owner is seeking to work with OEMs of skincare and cosmetic products to advance their business where sample testing are available.  The cellulose are fabricated into nano-sized to deliver the excellent properties such as:  Water retention: Nano structure of fibrils are rich with hydroxyl group to bond and interact with active compound. Gel and film forming: Nano structure of fibrils can overlap to form nanolayer film on the target area. High biocompatibility: Tested on human cell model. Surfactant: Emulsifier, texture and viscosity modifier. Carrier for actives: To replace chemical compounds in skincare and cosmetics. Improved the release of actives more than 10x.  The potential applications of the ingredient in skincare and cosmetic products include:  Exfoliating Scrub: Gently removes dead skin cells and impurities. Mask sheet: Increase moisture, store, and release active ingredients while adhering to the skin and forming a protective film. Creams and lotions: Helps to improve texture, smoothness, increase moisture, dispersion, retention, and release of active ingredients. Nail polish: Helps adhere to the surface and create a film layer. Nanofibrillated cellulose can also be used in the field of healthcare for wound dressings, drug delivery, medical diagnostics, smart sensors and electronic skin.  The global skincare sector was valued at $131.5 billion in 2022 and is forecasted to generate a CAGR of 4% over 2022–2027, to reach $160.2 billion in 2027. In volume terms, the sector is forecasted to grow from 17.3 billion units in 2022 to 18.6 billion units in 2027, at a CAGR of 1.4%. Thailand's skincare market generated a revenue of $466.80 million in 2022, making it a significant sector of economic growth.  Sustainability: To offer a sustainable solution to petroleum-based materials commonly used in skincare products. This addresses the growing demand for environmentally friendly and renewable ingredients. In Thailand, cellulose is produced from biomass which is abundant and are common upcycling materials. Consumer Health: It is designed with a focus on consumer health, as it does not pose the health challenges (such as skin irritation and allergies) as some of the current skincare chemicals and materials on the market. Versatile Application: The material has a wide range of applications in skincare and cosmetics, serving as a thickening agent, emulsifier, humectant, texture and viscosity modifier. This versatility makes it valuable for various product formulations. Biocompatibility: It boasts excellent biocompatibility, ensuring that it is well-suited for use on the skin, which is crucial for skincare and cosmetic products. Regulatory Compliance: Given the increasing regulatory scrutiny on skincare product ingredients, this material is FDA-approved and GRAS certified for safe and compliant ingredients. Scalable: Less expensive than petroleum-based materials, excellent biodegradability and mechanical strength while being resistant to high heat and chemical. Bioingredient, Skincare, Nanotechnology, Biocompatible material Materials, Nano Materials, Personal Care, Cosmetics & Hair, Healthcare, Medical Devices

This technology involves the development of a spray designed to enhance immunity and combat inflammation while effectively inhibiting respiratory viruses, including H1N1, RSV, and COVID-19, as demonstrated in pre-clinical testing. The product is a result of a comprehensive process, starting from the cultivation of specific target plants for extracting key compounds, leading to formulation development, and culminating in non-clinical and clinical studies. The primary problem addressed by this technology is the need for effective virus prevention and inflammation reduction, particularly among individuals interested in maintaining their health and preventing viral infections, such as reducing susceptibility to respiratory diseases. The target audience for this technology includes individuals who are interested in proactive health maintenance and seek to protect themselves from viral infections while mitigating inflammation-related health issues. This IP addresses a significant need in the marketplace by offering a proactive solution for individuals looking to bolster their immune systems and reduce the risk of viral infections, which has become especially pertinent in the context of the COVID-19 pandemic. Furthermore, the technology's focus on inflammation reduction aligns with the growing awareness of the importance of immune system support and overall health optimization, making it a relevant and valuable innovation for health-conscious consumers. The technology owner is seeking for licensing and R&D collaborations into other various applications. The technical features and specifications of this innovative virus prevention and immune enhancement spray can be described as follows: Active Ingredients: The spray contains a proprietary blend of natural compounds derived from specific target plants known for their antiviral and anti-inflammatory properties. These active ingredients are carefully extracted and formulated to ensure maximum efficacy. Formulation: The technology involves a specialized formulation process that optimizes the stability and bioavailability of the active ingredients. This ensures that the spray can effectively deliver the desired benefits when applied. Virus Inhibition: The spray has been rigorously tested and proven to inhibit a range of respiratory viruses, including H1N1, RSV, and COVID-19, at a pre-clinical level. Specific data on the extent of virus inhibition and the mechanism of action may be provided as part of the product's technical specifications. Anti-Inflammatory Effects: Apart from virus inhibition, the technology addresses inflammation reduction. It includes compounds that help mitigate inflammation, which is a key aspect of supporting overall health and reducing the risk of various chronic diseases. With its focus on virus prevention, immune enhancement, and inflammation reduction, this technology has a wide range of potential applications across several industries such as:  Health and Wellness Supplements: Dietary supplements and capsules containing the active ingredients for daily immune support. Immunity-boosting powders or effervescent tablets for easy consumption. Multivitamin formulations enriched with these active compounds. Pharmaceuticals: Antiviral medications for specific viral infections, developed using the active ingredients as a basis while dosage depend on product type. Anti-inflammatory drugs designed to address chronic inflammation-related diseases. Beyond viral, immune, and inflammatory protection, this technology is in the midst of researching additional functions, such as the ability to kill cancer cells, control blood sugar, and aid in the prevention of heart disease. All of these potential benefits are currently under study and research. Personal Care and Cosmetics: Skincare products like serums and creams formulated to reduce skin inflammation and promote healthy skin. Lip balms or oral care products with antiviral properties for oral health. Hospitality and Travel: Antiviral sprays or wipes for disinfecting surfaces in hotels, airplanes, and public transportation. Immunity-boosting amenities or offerings in hospitality services to enhance guest health and safety. The heightened awareness of immune health and viral protection due to COVID-19 pandemic, coupled with an ageing population growing demand for immune support and inflammation- reducing products, underscores the relevance of this technology. The trend of health-conscious consumers actively seeking well-being solutions further enhances its market appeal. While the exact market size may vary based on location and specific applications, these factors collectively suggest a significant and expanding market for this technology, contingent on effective marketing, distribution, and adherence to regulatory standards. Antiviral Properties: This technology has antiviral properties against various viruses, such as influenza H1N1, COVID-19, as well as RSV.  Broad-spectrum antiviral efficacy achieved using natural and sustainable ingredients. Anti-inflammatory Effects: Inflammation plays a pivotal role in the body's immune response. This technology has demonstrated anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines. This can potentially modulate the immune response and reduce the severity of diseases like allergies and asthma. Mast Cell Stabilization: This technology has been shown to stabilize mast cells and reduce the release of histamine, which is implicated in allergic responses. Improved Pharmacokinetics: Natural extracts usually exhibits low pharmacokinetics, the technology encompass processes to enhance the pharmacokinetics of these extracts, making them more bioavailable and effective. Besides the oral spray, a nasal spray formulation is in development. Compatibility: The extracts are tailored to be compatible with water-based products, further broadening their potential applications. The technology presents itself as a versatile, science-backed, and holistic approach to wellness. Unlike many single-purpose application, this technology offers a well-rounded and forward-thinking solution that addresses multiple facets of health, setting it apart as a transformative and indispensable innovation in the field. Oral Spray, Botanical Drugs, Respiratory Diseases Personal Care, Nutrition & Health Supplements, Healthcare, Pharmaceuticals & Therapeutics

Helicobacter pylori (H. pylori) infection affects over 50% of the global population and is a major cause of gastritis, peptic ulcers, and gastric cancer. Current antibiotic regimens face challenges such as antibiotic resistance and adverse effects. Natural products provide a promising alternative, but their efficacy must be scientifically validated before clinical use. To address this need, we have developed an in vitro platform to evaluate anti-H. pylori properties of botanical extracts in a robust and reproducible manner. The model comprises two components: 1) Direct antimicrobial activity determined by minimum inhibitory and bactericidal concentrations; 2) Anti-infective effects against live H. pylori infection of gastric epithelial cells. Using this platform, we have evaluated the anti-H. pylori properties of Boesenbergia rotunda (fingerroot) extracts. This provides evidence for the traditional use of fingerroot and validates it as an herbal medicine candidate. Our in vitro infection model allows rapid screening of natural product libraries to discover novel anti-H. pylori phytotherapies. It offers a standardized method as a part of a preclinical evaluation of safety and efficacy prior to human trials. This platform could be utilized by nutraceutical or pharmaceutical companies interested in scientifically developing new botanical therapies for H. pylori infection and gastritis. It addresses the need for evidence-based natural medicines to combat antibiotic resistance and improve treatment options against a global infection. Besides uncovering novel targets for traditional medicine, the technology owner is able to provide screening, extraction, compound analysis and validation tests for natural compounds at the facilities.  This technology consists of an in vitro infection model using the human gastric epithelial cell line AGS to evaluate anti-Helicobacter activity of natural extracts. The AGS cells are obtained from a reputable source (ATCC) and cultured under recommended conditions. The H. pylori strain is acquired from an accredited repository (ATCC). Assay parameters are established as per CLSI guidelines to ensure quality control. The AGS cells are infected with a standardized inoculum of H. pylori and co-incubated with the test extracts. After infection, H. pylori burden is quantified using immunofluorescence with antibodies specific to H. pylori and high-throughput imaging with the Operetta system. This provides a robust and reproducible platform to quantify the anti-Helicobacter efficacy of natural extracts in a physiologically relevant gastric cell model. Pharmaceutical industry: Drug discovery screening for new anti-H. pylori agents Preclinical validation of lead therapeutic compounds Evaluating combination therapies with antibiotics Nutraceutical industry: Substantiating health claims of traditional medicines and botanicals Developing supplements and functional foods for H. pylori infection Diagnostics industry: Testing for antibiotic susceptibility of clinical isolates Academic research: Investigating H. pylori pathogenesis in gastric cells Screening novel anti-infective approaches like nanoparticles Food industry: Testing natural extracts and food products for anti-H. pylori effects Developing functional foods with anti-H. pylori benefits Ideal partners for collaboration and value chain integration include: Natural product companies/academic groups with extracts libraries to screen Contract Research Organizations (CROs) that perform assay development and High Throughput Screening (HTS) Gastroenterology researchers and hospitals that can provide H. pylori clinical isolates and patient samples  HTS system distributors for supporting imaging and analysis Pharma/nutraceutical companies for commercialization of validated lead extracts The global market for Helicobacter pylori infection treatment is poised for robust growth, expected to reach US$ 1.26 billion by 2033 as per Future Market Insights. Rising prevalence coupled with antibiotic resistance drives demand for novel therapies. The technology provides a reliable in-house in vitro screening platform for the development of scientifically validated phytotherapies and functional foods. Standardized validation will enable rapid translation into premium nutraceuticals and therapeutics for the underserved natural medicine segment. As H. pylori prevalence is higher in developing countries, a large market would be seeking cost-effective, efficacious and natural solutions. This presents a timely opportunity to license a cost-effective screening technology with applications across pharmaceuticals, supplements, and food. Our platform accelerates R&D and commercialization of alternative therapies to combat a growing global infection. The current state-of-the-art for anti-H. pylori drug discovery relies on conventional antimicrobial screening models that do not replicate human gastric physiology. This leads to poor translation from in vitro efficacy to clinical outcomes. Our approach provides a physiologically relevant infection model using human gastric cells that enables better predicting efficacy. The standardized and robust platform allows for a high throughput screening unmatched by current animal models in scale and cost. By accommodating natural product libraries, synthetic compounds, and combinations, it can unlock novel therapies beyond conventional antibiotics. The model helps to scientifically validate traditional medicines to meet regulatory and consumer demand for evidence-based natural options. With applications across pharmaceutical, nutraceutical, and food sectors, this versatile screening platform has the potential to outperform current state-of-the-art in replicating human gastritis pathology. Boesenbergia Rotunda, Fingerroot, Herbal Medicine, Helicobacter pylori Personal Care, Nutrition & Health Supplements, Healthcare, Pharmaceuticals & Therapeutics

In recent decades, Enterovirus 71 (EV71) and Coxsackies A16 (CA16), Herpes Simplex Virus type 1 (HSV-1) and/or Herpes Simplex Virus type 2 (HSV-2) have been the major cause of epidemic of several diseases worldwide. This technology presents an antiviral pharmaceutical composition using at least one plant-based compound as the therapeutic agent to inhibit viral replication in a host upon administering the composition to the subject accordingly. The composition comprises a polar extract of Astraeus asiaticus, and one or more pharmaceutically acceptable excipients selected from the group consisting of a solvent, an additive, a buffering agent, a preservative, a flavoring agent, and a stabilizer. The composition has shown to be effective against EV71, CA16, HSV-1, and/or HSV-2. EV71 and CVA16 are the primary cause of Hand-foot-and-mouth disease (HFMD) and herpangina. HSV-1/HSV-2 are the causative agent of oral/genital herpes. The composition can be formulated including, but not limited to, oral spray, oral paste and hand gel.  The discovery of this active ingredient A. asiaticus can significantly prevent EV71 infection where infants and children under five years old are more vulnerable to severe complications. Currently, there are no commercial product for Acyclovir-resistant strains but the active ingredient A. asiaticus is shown to be effective against HSV-1/HSV-2 and Acyclovir-resistant HSV infections. The technology owner is seeking collaborations with OEMs, pharmaceutical and health supplement companies for manufacturing and further R&D to formulate the active ingredient into health supplements.  An antiviral pharmaceutical composition comprising:  Polar extract of A. asiaticus. One or more pharmaceutically acceptable excipients consisting of a solvent, an additive, a buffering agent, a preservative, a flavoring agent, and a stabilizer, which is effective against viral replication within a host cell infected with a predetermined virus including Acyclovir-resistant HSV-1/2. A. asiaticus is water soluble but can be formulated with additives to dissolve in lipid solvent. The target market is worldwide especially in Asia such as China, East Asia, and Southeast Asia, where rates of EV71 and CVA16 infections are highly prevalent and increasing in Japan, Taiwan and Malaysia. There are plans to use the active ingredient for functional food/pills. It is estimated that oral and nasal products in Thailand have a value of 750 million baht and has been growing by 17% of market value over three years. There are no oral care products specific to the viruses and no specific medications for hand-foot-and-mouth disease. Even though there are vaccines for this disease, it has not effectively covered all variants of viruses. The technology is in the process of patent and approval from Thailand Food and Drug Administration.  Novel natural compound ingredient that is antiviral against Acyclovir-resistant strains. Extraction process can be applied to any manufacturer.  A. asiaticus can be sourced from ASEAN regions and has recently been shown to grow in culture media. Versatility of ingredient to be used in different formulations and compatibility with excipients.  Astraeus Asiaticus, Hand Foot and Mouth Disease, Herpes, Oral Spray, Oral Paste, Hand Gel Personal Care, Nutrition & Health Supplements, Healthcare, Pharmaceuticals & Therapeutics

Melioidosis, caused by the environmental gram-negative bacterium Burkholderia pseudomallei, is a tropical disease often manifesting as severe sepsis. In tropical regions where melioidosis is prevalent, the mortality rate for sepsis and melioidosis is alarmingly high with 40-80% of patients exhibiting bacteremia and pneumonia, underlining the urgent need for effective diagnostic solutions. Currently, available methods for identifying melioidosis patients are limited, contributing to under recognition and misdiagnosis of this fatal pathogen. In addressing this critical healthcare challenge, the ready-to-use real-time PCR kit for B. pseudomallei detection is a significant breakthrough. Its purpose is to enhance the diagnosis process for melioidosis suspected patients. The kit provides high sensitivity and quick diagnosis capabilities which are essential for timely patient management and clinical decision-making, enabling prompt administration of appropriate antimicrobial agents for melioidosis. This not only reduces disease severity but also impacts the mortality rate and the overall cost of hospital care. The gold standard for diagnosis is bacterial culture but has a low sensitivity of 60% and a low throughput rate, which does not meet the demands for quick and accurate detection in melioidosis cases. This technology addresses this gap by offering a rapid, highly sensitive diagnostic tool that is crucial to reduce severe infections that lead to high mortality rate. The technology owner is seeking collaborations with medical institutions (particularly those specializing in infectious disease diagnosis and treatment), device manufacturers capable of producing and distributing the kit at scale, research institutions and academic organizations. The technology consists of a comprehensive real-time polymerase chain reaction (PCR) kit, encompassing essential components including a real-time PCR master mix, specific primers, and a probe designed for detecting the B. pseudomallei. Additionally, the kit incorporates specific primers and a probe for internal control, a positive control, and a negative control. The inclusion of all these reagents and controls within the kit makes it a complete and user-friendly solution, particularly suited for medical institutions, notably hospitals with high workloads. The internal control within the kit is specifically constructed and instrumental in validating the extraction process and DNA amplification, enhancing the technology's reliability and accuracy. It not only aids in error detection but also enables immediate correction without requiring batch retesting, saving valuable time and resources. The high sensitivity and specificity of this real-time PCR kit significantly improve diagnostic accuracy and speed, leading to reduced patient mortality rates. The kit's versatility in detecting the target not only in clinical patient samples but also in diverse sample types like environmental samples extends its utility beyond clinical settings, making it valuable for epidemiological studies and research.  This technology finds its primary application within the medical industry in institutions, hospital facilities and research labs, particularly in the field of infectious disease detection, with a focus on melioidosis and other undifferentiated fever diseases in which the patients have. Although the reagent of this kit detects only B. pseudomallei, the internal control and mix reagents within the kit can be applied for other disease detection. The technology's adoption will catalyze a transformation in diagnostic methodologies and deepen our understanding of infectious diseases, fostering advancements in public health and bolstering the scientific ecosystem. Melioidosis is the third most common cause of death from infectious diseases after human immunodeficiency virus/acquired immunodeficiency syndrome and tuberculosis. The market potential for this technology is substantial, encompassing both endemic and non-endemic regions impacted by melioidosis. These regions include Southeast Asia, South Asia, United States and Australia where melioidosis poses a significant healthcare challenge and major public health concern. Clinically validated for the diagnosis of meliodosis in Thailand hospitals. High sensitivity of 89.6% and 96% specificity. Patented internal control construct, reagent mix and DNA extraction process. Diagnostic time reduced from 58-hours using bacterial culture to 3 hours using PCR. Enable high concentration of DNA extracted using plasma samples. Overcome previous low sensitivity of PCR testing with blood samples. The technology's intuitive user-centric design sets it apart from existing solutions where visual aids are lacking. Particularly, each reagent tube and internal control is color-coded labeled to reduce the risk of human error during preparation. The compact design ensures ease of use and storage, accessibility and streamlining processes, prioritizing user-friendliness in diagnostic process and making it an indispensable tool for healthcare professionals globally. Melioidosis, Burkholderia pseudomallei, Real-time PCR Kit Healthcare, Diagnostics, Medical Devices, Life Sciences, Biotech Research Reagents & Tools

Professional football clubs have a strong economic motivation to invest in injury prevention and rehabilitation programs. Among sports-related injuries, ankle sprains stand out as one of the most common injuries, accounting for 10-30% of such injuries. Even more concerning is the recorded data indicating that a substantial 80% of ankle sprains result in injury recurrence and enduring instability. This underscores the critical need for innovative solutions to address and prevent such joint injuries, ultimately enhancing players’ performance, prolonging their careers, and safeguarding the financial interests of professional football clubs. Through interdisciplinary research, the technology owner has developed a second skin designed to provide optimal support and protection for ankle joints, emerging as a promising avenue in the pursuit of minimizing these pervasive and recurrent injuries. This innovative second skin is made of a non-woven fabric that incorporates graphene fibers using a spraying technique. The application of this second skin should be prior to each practice session, as the level of support it provides decreases during physical activity. The second skin has remarkable performance and high impact resistance, ensuring a user-friendly experience. The technology owner is seeking collaboration with relevant partners, such as football clubs and sports medical centers in Asia and Europe. The prevention of ankle sprains is generally achievable by using external ankle supports, particularly for athletes with a history of ankle injuries. The technology owner has identified a significant issue related to the complexity of tap wrapping and developed a spray solution to replace tap wrapping in the market. The technology exhibits the following features: A novel combination of nano-materials: Polycaprolactone (PCL) and graphene Innovative application method: utilising a spay technique High impact resistance during sports activities Easy to apply with high efficiency User-friendly solution to enhance user comfort Environmentally friendly This technology can be used to support ankle movement during sports activities, including both training and competition. Potential applications include (but not limited to): Football and soccer Basketball Tennis Track and field Gymnastics Other sports and exercise Innovative formulations using nano-materials Easy to apply by utilising a spay technique Remarkable performance due to high impact resistance User-friendly and high comfortability Ankle injury, non-woven fabric, Spray support Materials, Composites, Nano Materials, Chemicals, Coatings & Paints

Nitrofurans are synthetic antibiotics that have been widely used in veterinary medicine to treat bacterial infections in animals. However, due to concerns about their potential harmful effects on human health, many countries have banned their use. As a result, it is important to detect nitrofurans residues in food products to ensure food safety and prevent potential health risks. The aptasensor colorimetric detection kit for nitrofurans (NFs) residues provides high specificity and sensitivity of NFs contaminants in fisheries products and honey. This kit enables the rapid extraction of NFs within 5 hours, without requiring sophisticated equipment. The kit also allows for rapid detection within 5 minutes, with the assistance of a mobile phone image analyzer application, making it ideal for on-site detection. The sensitivity of detection reaches 0.3 ppb, which is in line with the Minimum Required Performance Level (MRPL), allowing this kit to be used as a screening kit for NFs. Compared to the standard method, LC-MS/MS, this kit reduces the cost of operation by 10 times (from 100 USD to 10 USD) and reduces the time of operation (from 18 hours to 6 hours). Additionally, this kit does not require sophisticated scientific equipment. The technology provider is seeking R&D collaboration partners with the farming and feed production industry to self-determine NFs contaminants prior to harvesting or selling their products.   The nitrofurans aptasensor colorimetric detection technology includes several key features: Specificity: The aptamer is specific to nitrofurans and does not react to other chemicals. Efficient and rapid NFs extraction: The chemical extraction process has been shortened to 5 hours using a special equipment-free method. Rapid detection: The color change can be observed within 30 seconds and is easy to visualize. Quantitative: Image analysis on a mobile phone application assists in the quantitative analysis of NFs contaminants with standard. Acceptable accuracy: The accuracy of the detection is more than 95% and complies with the gold standard method.   The aptasensor nitrofurans detection kit is a convenient, economical, and instrument-free alternative for screening nitrofurans (NFs) contaminants in fisheries products. This kit allows farmers, frozen units, and animal feed production companies to monitor NFs contaminants more frequently and efficiently. The potential customers of our nitrofurans aptasensor colorimetric detection include: Frozen food import and export businesses: These businesses can screen the contaminants in fisheries products to reduce the cost of operations. The time of LC-MS/MS determination by the private sector is 14 days (100 USD). If the sample is found positive for NFs, it requires repeat analysis (another 14 days with another 100 USD). Therefore, the maximum waiting time for NFs analysis is 28 days, during which the frozen products are kept in the frozen unit, incurring additional costs. Animal feed production (live and feed pellet): These companies can screen and monitor the contaminants in live feed such as artemia and raw materials of feed pellet production to ensure there is no NFs contamination. Local farmers: Local farmers can screen and monitor the contaminants in animals to avoid harvesting NFs- contaminated aquatic animals that cannot be exported. The nitrofurans aptasensor colorimetric detection kit is a new on-site detection kit for nitrofurans, which is a class of antibiotics that are banned in many countries due to their potential to cause cancer. The kit offers several advantages over existing methods, including: Shorter nitrofurans extraction time (5 hours vs. 18 hours by conventional methods) Rapid test results (less than 5 minutes vs. more than 30 minutes by other methods) Cheaper testing costs (approximately 10 times cheaper than LC-MS/MS) No requirement for special instruments or skilled personnel in lab practice Reliable and accurate data The kit is therefore a significant improvement over existing methods for on-site nitrofurans detection, and it could have a major impact on food safety and public health. Nitrofurans, rapid detection kit, on-site detection, nitrofurans food screening, food safety and security

Piglets are vital to the pork industry, but they are often born weak and with insufficient milk, resulting in high mortality rates and the need for antibiotics. To address this issue, a technology provider has developed a formulation containing medium-chain fatty acids (MCFAs), which can help piglets recover quickly, disinfect bacteria, inhibit viruses, balance gut microorganisms, and improve immunity levels. The formulation contains a high concentration of lauric acid and monolaurin, which account for more than 40% of the total fatty acid content. It also contains natural extracts and curcuminoids from palm kernel oil with techniques decarboxylated that help reduce oxidative stress, stimulate the immune system, and reduce inflammation in the digestive tract of piglets. The technology provider is seeking collaboration partners to reduce antibiotic use in the pig industry, which will result in fewer chemical residues in meat and lower production costs. PKO and medium-chain fatty acids (highly digestible energy boosters) Monolaurin and High Lauric Acid (C12) (inhibits bacterial, and pathogenic viruses and boosts immunity) Natural extracts & curcuminoids Sterilization in Vacuum Mixer homogenize Specializes in the technology of nutritional supplement products for piglets and technical services for farms Livestock farming has been shifting its focus to reducing antibiotic use as one of the ways for pig farms to reduce production costs. Piglets in small groups often do not receive enough colostrum, leading to less energy to live on than normal and a higher risk of bacterial infection. The incidence of diarrheal diseases increases by more than 60-70%, causing piglets to be in a state of growth arrest with below-normal weaning weight. The formulation developed by the research team positively affects the level of immunity, reduces the risk of bacterial infection and viral infestation, reduces the mortality rate by more than 40-50%, and increases the weaning weight of piglets by more than 25-30%. It also contributes to the reduction of production costs. Preliminary results show that the formulation can reduce piglet mortality rate by 35% and diarrhoea rate by 45% while increasing the growth rate by more than 25% (P < 0.05). Total protein content, albumin content, and globulin are higher than in the control group (P < 0.05).   The formulation has excellent quality and is cheaper than the products currently available in the market. The Thai domestic market is estimated to account for about 3% or $377 million/year of the total livestock additives market due to the demand for meat products. There are also potential markets in Europe, Africa, and Canada. The Philippines and Vietnam are large markets for livestock feed additives with a higher market value than Thailand and the potential for formulation exports to both countries. The growth rate of the livestock feed additives market in both countries is expected to increase by 3.7%. The market share of total feed additives in Thailand, the Philippines, and Vietnam is expected to increase from $125 million/year to about $15 million/year. All ingredients used in the formulation are selected from natural extracts, with emphasis on using extracts that have the same potential as antibiotics. Through a standardized mixing process and tested for actual industrial use for more than 5 years. This formula and many other innovations are made with safe methods that have been tested and found safe by animal nutrition experts and researchers in Thailand. Life Sciences, Agriculture & Aquaculture, Industrial Biotech Methods & Processes

This technology aims to tackle the food waste problem in the Thai agricultural sector. Shrimp shell was selected since it constituted a large portion of all crustacean shell waste. Many tons of shrimp shells are discarded daily. However, they contain high amounts of protein, calcium, and umami compounds. Thus, they can be used to fortify food products.  Currently, the instant noodle market still has a limited number of healthy options. Therefore, there is a significant market opportunity to develop a low sodium and high protein instant noodle product. Main ingredients: Wheat flour, Shrimp shells Production process uses baking instead of frying of noodles No more than 550 g of sodium per serving (WHO recommended amount) Up to 16 g of protein per serving (Roughly twice of most instant noodles) Light taste of shrimp which provides umami flavor without additives This product can be sold in both B2C and B2B. B2C: Sold as a retail instant noodle product in supermarkets B2B: Sold to food service and HoReCa companies to be incorporated in a noodle dish on their menu Able to formulate into other types of noodles e.g. spaghetti and ramen In 2021, Mintel published a report showing a strong consumer shift towards convenience and health foods. As such, this product is targeted at students aged 17 to 23 looking for easy and healthy meals. According to a survey of Thai college students, most of them are aware of the high sodium and low nutritional value of instant noodles in the market and are looking for healthier alternatives. They also prioritize nutrition over prices, brands, and flavours. Therefore, this product’s nutritional value and price point will appeal to them greatly. This product is expected to capture 10% of the market share for Thai functional instant noodles within 5 years of launch. Lower sodium and higher protein content than normal instant noodles Natural umami flavor without additives Convenience, easy to prepare Affordable price point Sustainable production valorising food waste in line with Sustainable Development Goals Future Food, Shrimp Shells, Instant Noodles, Low Sodium, High Protein Foods, Ingredients, Sustainability, Food Security